The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
Using sequencing approaches, researchers are learning more about what drives breast cancer metastasis and resistance.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
Analysis of a gene associated with basal progenitor cell expansions in the brain suggests a single splice site change led to human-specific forms of the gene transcript.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.